Potential role of thymoquinone to treat gastrointestinal cancers: insights into its molecular mechanisms.

IF 3.1 4区医学 Q2 PHARMACOLOGY & PHARMACY

Naunyn-Schmiedeberg's archives of pharmacology Pub Date : 2025-03-05 DOI:10.1007/s00210-025-03861-1

Tina Rahjoo, Alireza Motamedzadeh, Felora Ferdosi, Ehsan Dadgostar, Michael Aschner, Hamed Mirzaei, Sina Ghesmatpour, Fatemeh Nabavizadeh, Fatemeh Rahmati-Dehkordi, Omid Reza Tamtaji

{"title":"Potential role of thymoquinone to treat gastrointestinal cancers: insights into its molecular mechanisms.","authors":"Tina Rahjoo, Alireza Motamedzadeh, Felora Ferdosi, Ehsan Dadgostar, Michael Aschner, Hamed Mirzaei, Sina Ghesmatpour, Fatemeh Nabavizadeh, Fatemeh Rahmati-Dehkordi, Omid Reza Tamtaji","doi":"10.1007/s00210-025-03861-1","DOIUrl":null,"url":null,"abstract":"<p><p>Gastrointestinal (GI) malignancies, including esophageal cancer, gastric cancer, and colon cancer, are associated with high mortality rates worldwide. Thymoquinone is one of the main bioactive components of Nigella sativa, and it has been documented to have anticancer effects including GI cancer. Thymoquinone inhibits GI cancer progression by inducing cell cycle arrest, apoptosis, and oxidative stress and inhibiting inflammation, migration, invasion, metastasis, histone deacetylases, STAT3, PI3K/AKT/mTOR, and Wnt/β-catenin signaling pathways. Although the beneficial effects of thymoquinone have been documented, some limitations, including poor bioavailability and hydrophobicity, have hindered its clinical application. Nanotechnology approaches bypass these limitations. In this review article, we outline the different cellular and molecular pathways influenced by thymoquinone and its nanoformulations in GI cancer.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-025-03861-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Gastrointestinal (GI) malignancies, including esophageal cancer, gastric cancer, and colon cancer, are associated with high mortality rates worldwide. Thymoquinone is one of the main bioactive components of Nigella sativa, and it has been documented to have anticancer effects including GI cancer. Thymoquinone inhibits GI cancer progression by inducing cell cycle arrest, apoptosis, and oxidative stress and inhibiting inflammation, migration, invasion, metastasis, histone deacetylases, STAT3, PI3K/AKT/mTOR, and Wnt/β-catenin signaling pathways. Although the beneficial effects of thymoquinone have been documented, some limitations, including poor bioavailability and hydrophobicity, have hindered its clinical application. Nanotechnology approaches bypass these limitations. In this review article, we outline the different cellular and molecular pathways influenced by thymoquinone and its nanoformulations in GI cancer.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Naunyn-Schmiedeberg's archives of pharmacology 医学-药学

CiteScore

6.20

自引率

5.60%

发文量

142

审稿时长

4-8 weeks

期刊介绍： Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.